Metastatic NSCLC with G719X/S781I EGFR-mutations with acquired BRAF V600E mutation - response to Osimertinib, Dabrafenib and Trametinib

被引：0
|
作者：
Urbanska, E. M. [1 ]
Sorensen, J. B. [1 ]
Melchior, L. C. [1 ]
Santoni-Rugiu, E. [1 ]
机构：
[1] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
acquired BRAF V600E; uncommon EGFR mutations; Osimertinib; Dabrafenib; Trametinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-06
引用
收藏
页码：S642 / S642
页数：1
相关论文
共 43 条
  • [1] Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
    Valet, Orion
    Swalduz, Aurelie
    Boussageon, Maxime
    Buisson, Adrien
    Avrillon, Virginie
    Mastroianni, Benedicte
    Perol, Maurice
    JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (06):
  • [2] Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy
    Huang, Yihua
    Gan, Jiadi
    Guo, Kunbin
    Deng, Yangyang
    Fang, Wenfeng
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : E236 - E237
  • [3] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Maurício Fernando Silva Almeida Ribeiro
    Franciele Hinterholz Knebel
    Fabiana Bettoni
    Rodrigo Saddi
    Karina Perez Sacardo
    Felipe Sales Nogueira Amorim Canedo
    João Victor Machado Alessi
    Andrea Kazumi Shimada
    José Flávio Gomes Marin
    Anamaria Aranha Camargo
    Artur Katz
    npj Precision Oncology, 5
  • [4] Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
    Silva Almeida Ribeiro, Mauricio Fernando
    Knebel, Franciele Hinterholz
    Bettoni, Fabiana
    Saddi, Rodrigo
    Sacardo, Karina Perez
    Nogueira Amorim Canedo, Felipe Sales
    Machado Alessi, Joao Victor
    Shimada, Andrea Kazumi
    Gomes Marin, Jose Flavio
    Camargo, Anamaria Aranha
    Katz, Artur
    NPJ PRECISION ONCOLOGY, 2021, 5 (01)
  • [5] Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
    Weng, C.
    Tang, K.
    Jin, S.
    Zhou, C.
    Yao, Y.
    Su, J-W.
    Chen, H.
    Liu, K.
    Li, Y.
    Yang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1688 - S1688
  • [6] Trametinib plus dabrafenib for unresectable or metastatic melanoma with BRAF V600E or V600K mutations
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (07): : 234 - 235
  • [7] Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation
    Zhou, Fei
    Zhao, Wencheng
    Chen, Xiaoxia
    Zhang, Jie
    Zhou, Caicun
    LUNG CANCER, 2020, 139 : 219 - 220
  • [8] Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
    Seo, Takuji
    Noguchi, Emi
    Yoshida, Masayuki
    Mori, Taisuke
    Tanioka, Maki
    Sudo, Kazuki
    Shimomura, Akihiko
    Yonemori, Kan
    Fujiwara, Yasuhiro
    Tamura, Kenji
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020, 2020
  • [9] Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation
    Ueberroth, Benjamin E.
    Lieu, Christopher H.
    Lentz, Robert W.
    JOURNAL OF GASTROINTESTINAL CANCER, 2024, 55 (03) : 1448 - 1452
  • [10] The Effectiveness of Osimertinib in a NSCLC Patient with Complex Uncommon EGFR Mutations of G719X and S768I: A Case Report
    Ma, K.
    Wang, X.
    Cai, Y.
    Xu, Y.
    Guo, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S935 - S935
12345